
MoonLake Immunotherapeutics: financial statements
Price
$11.07
November 20, 2026Market cap $942M
What Ploutos Investor adds for MoonLake Immunotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Operating income
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Operating income | -$54M | -$143M | -$245M | |
| Net income | -$36M | -$119M | -$227M | |
| Earnings per share | -$0.73 | -$1.89 | -$3.53 | |
| Earnings per share, basic | -$0.73 | -$1.89 | -$3.53 |
Financial statements
MLTX's revenue, profits and cash flows from 2021 to 2022, 2 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$1.6M
Finance leases
–
- Average discount rate
- 4.6%
- Lease cost for the year
- $1.5M
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Operating lease payments by year
Lease liability by year
Leases
MLTX's leases from 2022 to 2022, 1 more fiscal year
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 4 fiscal years.
Pension plans
Dec 31, 2025Defined-benefit pensions
100%funded
Surplus $9.0K.
The obligation is the present value of the pensions employees have already earned, at December 31, 2025. A deficit is the company's to fill with contributions. The filing
Pensions funded, by year
Pensions funded, by year
How far MLTX's pension plans were funded, from 2022 to 2022, 1 more fiscal year
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 4 fiscal years.
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
8.5%
Effective rate
-0.3%
The company paid -0.3% in tax on its profit, 8.8 points below the statutory rate it starts from (8.5%). Below, the reasons it gives.
Statutory rate
8.5%
Change in valuation allowance
-8.4 pts
Smaller lines (3)
-0.4 pts
Effective rate
-0.3%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.
Effective tax rate by year
The tax rate MLTX paid on its profit, from 2022 to 2022, 1 more fiscal year
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 4 fiscal years.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do MoonLake Immunotherapeutics's filings show?
These are MoonLake Immunotherapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much debt does MLTX have?
On December 31, 2025 MoonLake Immunotherapeutics had total assets of $424M, debt of $74M and shareholders' equity of $304M.
How much free cash flow does MLTX have?
In fiscal 2025 MoonLake Immunotherapeutics had cash from operations of -$196M and spent $35.0K on capital expenditure, leaving -$196M of free cash flow.
Where are the figures from?
From MoonLake Immunotherapeutics's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.